PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8351199-2	1993	Using Ba2+ (10 mM) as the charge carrier, inward currents sensitive to Cd2+ and nifedipine were potentiated by NPY in a concentration-dependent manner.	Nifedipine	80-90	neuropeptide Y	Homo sapiens	111-114	
8606797-6	1995	The effects of NPY were additive with nifedipine (at a supramaximal concentration of 5 microM), suggesting that NPY predominantly inhibits N-type Ca2+ channels present in these cells, and not L-type.	Nifedipine	38-48	neuropeptide Y	Homo sapiens	112-115	
2706916-2	1989	The effect of a single oral dose (10 mg capsule) of nifedipine on NPY- and NA-induced reductions of forearm blood flow (FBF) was studied in seven healthy volunteers.	Nifedipine	52-62	neuropeptide Y	Homo sapiens	66-69	
2706916-0	1989	Effect of oral administration of nifedipine on neuropeptide Y- and noradrenaline-induced vasoconstriction in the human forearm.	Nifedipine	33-43	neuropeptide Y	Homo sapiens	47-61	
2706916-3	1989	Intra-arterial infusions of NPY and NA into the brachial artery before nifedipine caused dose-dependent reductions in FBF with threshold doses of 0.2 and 0.03 nmol x min-1, respectively.	Nifedipine	71-81	neuropeptide Y	Homo sapiens	28-31	
2706916-6	1989	The NPY-induced decrease in FBF was slightly but significantly attenuated after compared to before nifedipine (19 +/- 6 vs. 28 +/- 5% at 1.0 nmol NPY x min-1; P less than 0.01).	Nifedipine	99-109	neuropeptide Y	Homo sapiens	4-7	
2461438-4	1988	The relaxant action of the calcium antagonist nifedipine on NPY-evoked contraction of cerebral arteries was not inhibited by a Ca++-deficient medium or by a high-Ca++ medium.	Nifedipine	46-56	neuropeptide Y	Homo sapiens	60-63	
3595720-7	1987	Nifedipine and felodipine reduced the contractile response to both NA and NPY on renal and skeletal muscle arteries.	Nifedipine	0-10	neuropeptide Y	Homo sapiens	74-77	
2468060-11	1988	Nifedipine slightly enhanced plasma NA and NPY-LI but not A during exercise.	Nifedipine	0-10	neuropeptide Y	Homo sapiens	43-46	
3595720-12	1987	In conclusion, NPY exerts a potent nifedipine-sensitive vasoconstrictor activity, especially on human skeletal muscle arteries in vitro, although the influx of extracellular calcium may not be a crucial mechanism.	Nifedipine	35-45	neuropeptide Y	Homo sapiens	15-18	
3595720-13	1987	The NPY-induced contractions of mesenteric veins and the inhibition of nerve-evoked [3H]NA efflux seem to be mediated via nifedipine resistant messenger systems.	Nifedipine	122-132	neuropeptide Y	Homo sapiens	4-7	
3595720-9	1987	Nifedipine still inhibited the NPY contractions in a Ca2+-free medium while high extracellular Ca2+ (7.5 mM) partly reduced the nifedipine effect.	Nifedipine	0-10	neuropeptide Y	Homo sapiens	31-34	
3595720-10	1987	NPY reduced the nerve stimulation-evoked [3H]NA overflow from the mesenteric veins via a nifedipine resistant mechanism.	Nifedipine	89-99	neuropeptide Y	Homo sapiens	0-3	
3028044-0	1986	Neuropeptide Y constricts human skeletal muscle arteries via a nifedipine-sensitive mechanism independent of extracellular calcium?	Nifedipine	63-73	neuropeptide Y	Homo sapiens	0-14	
3841402-8	1985	The calcium-entry antagonist nifedipine abolished both the NPY-induced contractions and the enhancement of NA-evoked contractions.	Nifedipine	29-39	neuropeptide Y	Homo sapiens	59-62	
2455193-14	1987	Calcium antagonists such as nifedipine inhibit the vasoconstrictor actions of NPY on arteries, but not on veins.	Nifedipine	28-38	neuropeptide Y	Homo sapiens	78-81